Frontiers in Oncology (Sep 2022)
Corrigendum: Highly invasive fluorescent/bioluminescent patient-derived orthotopic model of glioblastoma in mice
- Diana Yuzhakova,
- Elena Kiseleva,
- Marina Shirmanova,
- Vladislav Shcheslavskiy,
- Vladislav Shcheslavskiy,
- Daria Sachkova,
- Daria Sachkova,
- Ludmila Snopova,
- Evgeniya Bederina,
- Maria Lukina,
- Maria Lukina,
- Varvara Dudenkova,
- Gaukhar Yusubalieva,
- Gaukhar Yusubalieva,
- Tatyana Belovezhets,
- Daria Matvienko,
- Vladimir Baklaushev,
- Vladimir Baklaushev
Affiliations
- Diana Yuzhakova
- Institute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia
- Elena Kiseleva
- Institute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia
- Marina Shirmanova
- Institute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia
- Vladislav Shcheslavskiy
- Institute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia
- Vladislav Shcheslavskiy
- R&D Department, Becker&Hickl GmbH, Berlin, Germany
- Daria Sachkova
- Institute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia
- Daria Sachkova
- Institute of Biology and Biomedicine, Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia
- Ludmila Snopova
- Institute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia
- Evgeniya Bederina
- Institute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia
- Maria Lukina
- Institute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia
- Maria Lukina
- Laboratory of Molecular Oncology, Federal Research and Clinical Center of Physical and Chemical Medicine, Moscow, Russia
- Varvara Dudenkova
- Institute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia
- Gaukhar Yusubalieva
- Biomedical Research Center, Federal Research and Clinical Center, Federal Medical and Biological Agency, Moscow, Russia
- Gaukhar Yusubalieva
- Laboratory of Molecular Mechanisms of Regeneration and Aging, Engelhardt Institute of Molecular Biology, Moscow, Russia
- Tatyana Belovezhets
- Department of Molecular Immunology, Institute of Molecular and Cellular Biology SB RAS, Novosibirsk, Russia
- Daria Matvienko
- Department of Molecular Immunology, Institute of Molecular and Cellular Biology SB RAS, Novosibirsk, Russia
- Vladimir Baklaushev
- Biomedical Research Center, Federal Research and Clinical Center, Federal Medical and Biological Agency, Moscow, Russia
- Vladimir Baklaushev
- Laboratory of Molecular Mechanisms of Regeneration and Aging, Engelhardt Institute of Molecular Biology, Moscow, Russia
- DOI
- https://doi.org/10.3389/fonc.2022.1040637
- Journal volume & issue
-
Vol. 12
Abstract
No abstracts available.Keywords
- glioblastoma (GBM)
- primary cell line
- patient-derived xenograft (PDX)
- fluorescence imaging
- FLIM (fluorescence lifetime imaging microscopy)